Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsDividends payablesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsReceivables - AccuredRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

PharmaCyte Biotech (PMCB) Treasury Shares (2017 - 2026)

PharmaCyte Biotech (PMCB) has disclosed Treasury Shares for 5 consecutive years, with $45.0 million as the latest value for Q1 2026.

  • Quarterly Treasury Shares rose 1.29% to $45.0 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $45.0 million through Jan 2026, up 1.29% year-over-year, with the annual reading at $44.6 million for FY2025, 6.11% up from the prior year.
  • Treasury Shares for Q1 2026 was $15.3 million at PharmaCyte Biotech, up from $14.9 million in the prior quarter.
  • The five-year high for Treasury Shares was $15.3 million in Q1 2026, with the low at -$13.2 million in Q1 2024.
  • Average Treasury Shares over 5 years is $5.4 million, with a median of $9.2 million recorded in 2023.
  • The sharpest move saw Treasury Shares surged 1813.96% in 2023, then grew 0.91% in 2025.
  • Over 5 years, Treasury Shares stood at $5.5 million in 2022, then soared by 638.68% to $40.4 million in 2023, then grew by 9.29% to $44.2 million in 2024, then increased by 0.91% to $44.6 million in 2025, then grew by 0.9% to $45.0 million in 2026.
  • According to Business Quant data, Treasury Shares over the past three periods came in at $45.0 million, $44.6 million, and $44.6 million for Q1 2026, Q4 2025, and Q3 2025 respectively.